Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis
NCT03155932 · Arena Pharmaceuticals · PHASE2 · terminated · last registry update 2022-03-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision” | – | Registry record, Arena Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against S1PR1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-02-17Phase 3 first posted: Pfizer, etrasimod + Placebo (NCT05732454)
- 2023-01-05Phase 3 first posted: Viatris Innovation GmbH, Cenerimod + Placebo (NCT05672576)
- 2022-12-21Results posted on the registry: Arena Pharmaceuticals, Etrasimod + Placebo (NCT03996369)
- 2022-12-20Results posted on the registry: Arena Pharmaceuticals, Etrasimod + Placebo (NCT03945188)
- 2022-12-13Phase 3 first posted: Viatris Innovation GmbH, Cenerimod + Placebo (NCT05648500)
- 2022-12-09Phase 3 first posted: Bristol-Myers Squibb, Ozanimod + Placebo (NCT05644665)
- 2022-11-04Results posted on the registry: Arena Pharmaceuticals, Etrasimod 1 mg + Etrasimod 2 mg (NCT04162769)
- 2022-07-22Phase 3 first posted: Bristol-Myers Squibb, Ozanimod (NCT05470985)
- 2022-06-23Phase 3 first posted: Priothera SAS, mocravimod (NCT05429632)
- 2021-11-26Results posted on the registry: Arena Pharmaceuticals, Etrasimod + Placebo (NCT02536404)
- 2021-11-17Phase 3 first posted: Hoffmann-La Roche, Ocrelizumab + Fingolimod (NCT05123703)
- 2021-10-13Phase 3 first posted: Bristol-Myers Squibb, Ozanimod (NCT05076175)
- 2021-09-01Results posted on the registry: Celgene, RPC1063 + Placebo (NCT02435992)
- 2021-08-31Phase 3 first posted: Celgene, Tetanus, diphtheria, and acellular pertussis vaccine + Pneumococcal polysaccharide vaccine (NCT05028634)
- 2021-07-29Also stopped (terminated): Charite University, Berlin, Germany, Verum arm receiving Gilenya® + Active Comparator receiving Extavia® (NCT01647880)
- 2021-07-22Also stopped (withdrawn): Second Affiliated Hospital, Zhejiang University, School of Medicine, Fingolimod (NCT02956200)
- 2021-06-15Phase 3 first posted: Novartis Pharmaceuticals, Fingolimod + Ofatumumab (NCT04926818)
- 2021-06-14Phase 3 first posted: State University of New York at Buffalo, Mayzent + Ocrevus (NCT04925557)
- 2021-06-11Results posted on the registry: Actelion, ponesimod + teriflunomide (NCT02425644)
- 2021-06-11Results posted on the registry: Actelion, ACT-128800 Dose 1 + Placebo (NCT01006265)
- 2021-06-11Results posted on the registry: Arena Pharmaceuticals, APD334 (NCT03072953)
- 2021-06-11Also stopped (terminated): Arena Pharmaceuticals, APD334 (NCT03072953)
- 2021-06-07Results posted on the registry: Novartis Pharmaceuticals, BAF312 solution + Matching Placebo for BAF312 solution (NCT03338998)
- 2021-05-18Results posted on the registry: Actelion, Ponesimod (NCT02907177)
- 2021-05-18Also stopped (terminated): Actelion, Ponesimod (NCT02907177)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision